Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

This week, medication savings platform GoodRx announced a partnership with Novo Nordisk – the company behind Ozempic and ...

Novo Nordisk A/S is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for high US drug prices.Patients can now get Ozempic for $499 a month — about ...

Who benefits? The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...